US FDA Grants Orphan Drug and Rare Pediatric Disease Designations to GEn1E Lifesciences’ Dual Signal Modulator for the Treatment of Duchenne Muscular Dystrophy
GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven precision medicines for immunology, inflammation, and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) to GEn-1123 for the treatment of Duchenne Muscular Dystrophy (DMD).
